April 24th 2024
In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
23rd Annual International Congress on the Future of Breast Cancer® West
July 12-13, 2024
Register Now!
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
FDA Clears Image Processing Software with Emphasis on Nuclear Medicine Imaging Workflow
June 21st 2023The InterView Fusion and InterView XP reportedly improve image quality for single-photon emission computed tomography (SPECT) and offer imaging tools specifically geared to common nuclear medicine studies ranging from bone imaging to cardiac assessment and lung imaging.
Brain PET Study Suggests Link Between Early Amyloid Accumulation and Repetitive Subconcussive Trauma
May 9th 2023After five months of exposure to repeated blast events, the majority of nine otherwise healthy military instructors had significantly increased amyloid deposition in the brain, according to positron emission tomography (PET) findings from a new study.
Is PET/CT Better than CT for Monitoring Metastatic Breast Cancer Treatment?
April 10th 2023A recent prospective study found that progression-free survival (PFS) and disease-specific survival (DSS) were significantly associated with breast cancer tumor treatment response on 2-(18F)FDG-PET/CT imaging in comparison to contrast-enhanced computed tomography (CT), which showed no evidence of a significant association with tumor response.